Cambridge Healthtech Institute 第3回

Oncolytic Virus Immunotherapy

( 腫瘍溶解性ウイルスを利用した免疫療法 )

大きな可能性を持つ腫瘍溶解性ウイルス療法の商業化

2018年8月27日~28日

腫瘍溶解性ウイルスを利用した免疫療法をテーマにしたこのカンファレンスプログラムでは、製薬会社や研究機関で指導的な役割を担っている研究者が一堂に会し、腫瘍溶解性ウイルスを利用した免疫療法の開発を加速させるために必要となる重要なステップをめぐって議論を展開する予定であり、デリバリーや併用療法の戦略、ウイルスの開発、製品についての重要な最新情報なども紹介します。

Coverage will include, but is not limited to:

Latest updates and future directions in oncolytic virus immunotherapy

  • Update on recent deals, science and collaborations - what are the market dynamics - types of viruses (Herpes, Adeno, Vaccinia)
  • Feedback from big pharma, Pfizer, Amgen's post T-Vec OV portfolio
  • What needs to happen to take OVs forward
  • Update from companies with late-stage products/approvals - post-market approvals

Oncolytics in an era of combination therapies

  • Are combinations the only way forward for oncolytics?
  • Examples of successful combination models - checkpoints, CAR Ts, kinase inhibitors, alternative to checkpoints, antibodies
  • Issues when combining OVs - feedback on trials
  • Evidence to support role of oncolytics as monotherapies?

Improving OV potency, targeting and efficacy

  • Engineering strategies to improve efficacy and specificity - highly armed OVs
  • New virus, mechanism of actions
  • Tumor targeted delivery - latest from Ignite
  • Impact of tumor microenvironment - vascularization

Improving delivery and administration

  • Oncolytics as a single shot vs. multiple shots - mechanisms of action, evidence-based medicine
  • IV vs. systemic - dosage, delivery, delivery when combining with PD-1s
  • Evidence to support systemic route, what data is available

Oncolytics in development: Update on major clinical and preclinical therapies

  • Clinical updates - results, safety, efficacy issues, patient selection, setting endpoints, presenting data to physicians
  • Lessons learned in the clinic - translational strategies, novel preclinical models, biomarkers
  • Regulatory expectations -what to submit to regulators, data to include, feedback

* 不測の事態により、事前の予告なしにプログラムが変更される場合があります。

Choose your language
Traditional Chinese
Simplified Chinese
Korean
English





メール配信サービス